Latest news with #UnitedTherapeutics
Yahoo
21 hours ago
- Business
- Yahoo
United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag
We recently published United Therapeutics Corporation stands eighth among the most undervalued stocks. United Therapeutics Corporation (NASDAQ:UTHR) is among the most undervalued stocks to invest in. It is a biotechnology company focused on treating pulmonary arterial hypertension (PAH) and advancing organ transplantation alternatives through xenotransplantation and regenerative medicine. On June 23, 2025, United Therapeutics Corporation (NASDAQ:UTHR) announced the completion of enrollment in its Phase 3 ADVANCE OUTCOMES trial for ralinepag, a once-daily oral prostacyclin receptor agonist for PAH. The trial enrolled 728 patients, and top-line data is expected in the first half of 2026. Ralinepag showed strong Phase 2 results, significantly reducing pulmonary vascular resistance, a key marker of disease progression. The successful enrollment marks a major milestone as ralinepag could become a new standard of care, offering a more convenient and potentially more effective oral therapy for PAH. This move strengthens the company's leadership in PAH, complementing its existing Tyvaso franchise and advancing its pipeline of differentiated therapies aimed at improving patient outcomes. A healthcare professional wearing a health communications device discussing patient data with a colleague. United Therapeutics Corporation (NASDAQ:UTHR) is also presenting long-term ralinepag data at leading scientific conferences, reinforcing its commitment to transparency and scientific rigor. While exploring related areas such as idiopathic pulmonary fibrosis (IPF) and organ transplant innovations, the company's near-term focus remains firmly on transforming PAH treatment through innovative, patient-friendly therapies. While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Morgan Stanley Trims United Therapeutics (UTHR) Price Target, Maintains Buy Rating
United Therapeutics Corporation (NASDAQ:UTHR) is one of the high-margin pharma stocks to buy now. Morgan Stanley has lowered its price target on United Therapeutics (NASDAQ: UTHR) to $328 from $348, while maintaining an Equal Weight rating, amid broader headwinds facing the biotech and pharmaceutical sectors. The firm flagged persistent macroeconomic challenges and regulatory uncertainties that continue to weigh on investor sentiment across the space. A team of scientists in a laboratory, running tests on a biotechnology product. In a research note to clients, the firm pointed to several factors pressuring large-cap healthcare names this year, including policy volatility around drug pricing, ongoing debates over international transfer pricing, and staffing turnover at the FDA. Against that backdrop, United Therapeutics is facing specific questions about near-term sales performance, particularly around its key pulmonary arterial hypertension therapy, Tyvaso. Morgan Stanley is now modeling second-quarter Tyvaso sales of $442 million, below the Street consensus of $483 million. Total revenue is expected to reach $768 million, also under consensus estimates of $805 million. The firm attributes the cautious outlook to potential softness in Tyvaso DPI uptake and less momentum in patient onboarding than previously projected. Despite strong fundamentals and long-term growth driver, including its organ manufacturing pipeline, Morgan Stanley appears to be taking a more conservative stance in the near term. With shares already reflecting much of the upside potential, the firm sees a more balanced risk-reward profile at current levels. While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
6 days ago
- Business
- Business Wire
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here: Forward-Looking Statements Statements included in this press release that are not historical in nature are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 16, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
Yahoo
12-07-2025
- Business
- Yahoo
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) is one of the 11 best debt-free stocks to invest in right now. The company boasts a strong portfolio led by Tyvaso, its inhaled therapy for pulmonary hypertension, and a growing pipeline targeting pulmonary arterial hypertension (PAH). Its existing therapies are leading to stronger topline and earnings growth; the 17% year-over-year growth in Q1 2025 revenue and a 17% compounded annual growth rate (CAGR) over the last five years are evidence of that. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. UBS analyst Ashwani Verma maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) on June 30 but adjusted the price target to $385 from $410, reflecting a recalibration of expectations ahead of a key clinical update. Verma pointed to the company's upcoming Phase III readout for idiopathic pulmonary fibrosis (IPF), expected in the third quarter, as a potential high-impact event that could meaningfully influence the stock. While binary in nature, the analyst believes the risk/reward remains attractive at current valuation levels. Verma also highlighted Tyvaso as a continued bright spot for the company. He expects the therapy to see seasonally strong performance in both Q2 and Q3, which should support near-term revenue momentum. While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-06-2025
- Business
- Yahoo
United Therapeutics Announces World's First Bioengineered External Liver Treatment in Clinical Study
United Therapeutics Corporation (NASDAQ:UTHR) is one of the most undervalued US stocks according to analysts. On June 24, United Therapeutics Corporation and Intermountain Health announced a medical breakthrough: the world's first patient treated in a clinical study with a bioengineered external liver assist product called miroliverELAP. This historic procedure marked the first human clinical trial of a manufactured organ alternative and was performed at Intermountain Medical Center in Murray, Utah, by a team led by Christopher J. Danford, MD, who is a transplant hepatologist at Intermountain Health. The patient treated was experiencing liver failure and was not eligible for a liver transplant. A team of scientists in a laboratory, running tests on a biotechnology product. MiroliverELAP was developed by Miromatrix Medical Inc., which is a subsidiary of United Therapeutics and is an external liver assist combination product. It comprises a single-use MIRO-001 bioengineered liver and an extracorporeal blood circuit, designed to provide temporary liver support for patients with acute liver failure/ALF. ALF is a severe condition characterized by a rapid loss of liver function, often in individuals with no prior history of liver disease. United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally. While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
